These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39187034)

  • 1. Polymeric nanoparticles as a promising platform for treating triple-negative breast cancer: Current status and future perspectives.
    Bazzazan MA; Fattollazadeh P; Keshavarz Shahbaz S; Rezaei N
    Int J Pharm; 2024 Oct; 664():124639. PubMed ID: 39187034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymeric nanomaterials-based theranostic platforms for triple-negative breast cancer (TNBC) treatment.
    Reddy Baddam S; Ganta S; Nalla S; Banoth C; Vudari B; Akkiraju PC; Srinivas E; Tade RS
    Int J Pharm; 2024 Jul; 660():124346. PubMed ID: 38889853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
    Miller-Kleinhenz JM; Bozeman EN; Yang L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
    Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
    ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanosoldiers: A promising strategy to combat triple negative breast cancer.
    Pawar A; Prabhu P
    Biomed Pharmacother; 2019 Feb; 110():319-341. PubMed ID: 30529766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Advances in Triple Negative Breast Cancer Treatment: Focus on Poly (L-lactide-coglycolide) Nanoparticles.
    Towner RA; Dissanayake R; Ahmed M
    J Pharmacol Exp Ther; 2024 Jun; 390(1):53-64. PubMed ID: 38580448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
    He X; Cai K; Zhang Y; Lu Y; Guo Q; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Li C; Sun T; Cheng J; Jiang C
    ACS Appl Mater Interfaces; 2018 Nov; 10(46):39455-39467. PubMed ID: 30362704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
    Schettini F; Giuliano M; De Placido S; Arpino G
    Cancer Treat Rev; 2016 Nov; 50():129-141. PubMed ID: 27665540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy.
    He X; Zhang J; Li C; Zhang Y; Lu Y; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Guo Q; Sun T; Cheng J; Jiang C
    Theranostics; 2018; 8(18):4884-4897. PubMed ID: 30429875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
    Valcourt DM; Dang MN; Scully MA; Day ES
    ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remotely Phototriggered, Transferrin-Targeted Polymeric Nanoparticles for the Treatment of Breast Cancer.
    Jadia R; Kydd J; Rai P
    Photochem Photobiol; 2018 Jul; 94(4):765-774. PubMed ID: 29427385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
    Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
    J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
    Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
    Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release.
    Ma Y; Xie D; Chen Z; Shen X; Wu X; Ding F; Ding S; Pan Y; Li F; Lu A; Zhang G
    J Transl Med; 2024 Jul; 22(1):604. PubMed ID: 38951906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.
    Wang T; Subramanian C; Yu M; White PT; Kuai R; Sanchez J; Moon JJ; Timmermann BN; Schwendeman A; Cohen MS
    Surgery; 2019 Dec; 166(6):1168-1175. PubMed ID: 31371177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.